Alyeska Investment Group L.P. acquired a new stake in Stryker Corporation (NYSE:SYK - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 167,524 shares of the medical technology company's stock, valued at approximately $52,743,000.
Other large investors have also bought and sold shares of the company. Private Harbour Investment Management & Counsel LLC raised its holdings in Stryker by 0.9% during the 2nd quarter. Private Harbour Investment Management & Counsel LLC now owns 3,927 shares of the medical technology company's stock worth $1,236,000 after buying an additional 34 shares during the period. Flputnam Investment Management Co. lifted its position in Stryker by 64.1% in the 2nd quarter. Flputnam Investment Management Co. now owns 137,133 shares of the medical technology company's stock worth $43,175,000 after buying an additional 53,552 shares in the last quarter. Davidson Investment Advisors boosted its position in Stryker by 3.3% during the second quarter. Davidson Investment Advisors now owns 1,296 shares of the medical technology company's stock valued at $408,000 after purchasing an additional 41 shares during the last quarter. Nichols & Pratt Advisers LLP MA lifted its holdings in shares of Stryker by 7.3% during the 2nd quarter. Nichols & Pratt Advisers LLP MA now owns 57,022 shares of the medical technology company's stock valued at $17,953,000 after buying an additional 3,856 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in Stryker by 4.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 45,200 shares of the medical technology company's stock worth $14,231,000 after acquiring an additional 2,057 shares in the last quarter. Institutional investors own 77.09% of the company's stock.
Analysts Set New Price Targets
SYK has been the topic of a number of recent analyst reports. BTIG Research dropped their price target on shares of Stryker from $371.00 to $358.00 and set a "buy" rating on the stock in a research report on Friday, July 31st. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a "buy" rating and a $400.00 price objective on the stock. Royal Bank Of Canada dropped their price target on shares of Stryker from $435.00 to $420.00 and set an "outperform" rating for the company in a research report on Friday, July 31st. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Finally, Piper Sandler reduced their target price on Stryker from $420.00 to $390.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $386.28.
Read Our Latest Stock Analysis on Stryker
Insiders Place Their Bets
In related news, insider Dylan Bram Crotty sold 441 shares of Stryker stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider directly owned 6,102 shares of the company's stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Debra King sold 826 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. This trade represents a 11.74% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 351,267 shares of company stock worth $118,197,701 in the last 90 days. Company insiders own 4.60% of the company's stock.
Stryker Stock Performance
Shares of SYK stock opened at $331.32 on Monday. The company has a market capitalization of $127.08 billion, a P/E ratio of 34.33, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.86. The company's 50 day moving average price is $329.10 and its two-hundred day moving average price is $331.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16.
Stryker (NYSE:SYK - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 earnings per share. The firm's revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, analysts expect that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.
Stryker Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker's dividend payout ratio is presently 36.48%.
Stryker Company Profile
(
Free Report)
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
